The Effect of Caffeine on Ischemic Preconditioning

This study has been completed.
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University Identifier:
First received: September 12, 2005
Last updated: November 28, 2006
Last verified: February 2006

September 12, 2005
November 28, 2006
September 2003
Not Provided
Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.
Same as current
Complete list of historical versions of study NCT00184912 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Effect of Caffeine on Ischemic Preconditioning
Caffeine Reduces Acute Ischemic Preconditioning

Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption, we aimed to assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle.

24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or saline before a protocol for IP.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
  • Caffeine
  • Ischemic Preconditioning
  • Ischemia-Reperfusion Injury
  • Drug: caffeine
  • Drug: Technetium-TC99m-labeled Annexin A5
  • Procedure: ten minutes forearm ischemia
  • Procedure: ischemic forearm exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2006
Not Provided

Inclusion Criteria:

  • healthy male volunteers

Exclusion Criteria:


18 Years to 50 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigator: Gerard Rongen, MD, Phd Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology
Radboud University
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP